These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 29318564)

  • 1. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
    Piperigkou Z; Manou D; Karamanou K; Theocharis AD
    Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
    Gialeli C; Theocharis AD; Karamanos NK
    FEBS J; 2011 Jan; 278(1):16-27. PubMed ID: 21087457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix Metalloproteinases: A challenging paradigm of cancer management.
    Alaseem A; Alhazzani K; Dondapati P; Alobid S; Bishayee A; Rathinavelu A
    Semin Cancer Biol; 2019 Jun; 56():100-115. PubMed ID: 29155240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
    Winer A; Adams S; Mignatti P
    Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.
    Abdel-Hamid NM; Abass SA
    Mol Biol Rep; 2021 Sep; 48(9):6525-6538. PubMed ID: 34379286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seesaw of matrix metalloproteinases (MMPs).
    Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
    J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).
    Li X; Wu JF
    Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):109-41. PubMed ID: 19951249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
    Shi Y; Ma X; Fang G; Tian X; Ge C
    NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches?
    Koutroulis I; Zarros A; Theocharis S
    Expert Opin Ther Targets; 2008 Dec; 12(12):1577-86. PubMed ID: 19007324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
    Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
    J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase inhibitors.
    Ramnath N; Creaven PJ
    Curr Oncol Rep; 2004 Mar; 6(2):96-102. PubMed ID: 14751086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases as therapeutic targets in cancer.
    Vihinen P; Ala-aho R; Kähäri VM
    Curr Cancer Drug Targets; 2005 May; 5(3):203-20. PubMed ID: 15892620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic Roles of Metalloproteinases in Hematological Malignancies: an Update.
    Chaudhary AK; Chaudhary S; Ghosh K; Nadkarni A
    Asian Pac J Cancer Prev; 2016; 17(7):3043-51. PubMed ID: 27509927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs).
    Rangasamy L; Geronimo BD; Ortín I; Coderch C; Zapico JM; Ramos A; de Pascual-Teresa B
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31426440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases in the pathophysiology and progression of gynecological malignancies: could their inhibition be an effective therapeutic approach?
    Memtsas V; Zarros A; Theocharis S
    Expert Opin Ther Targets; 2009 Sep; 13(9):1105-20. PubMed ID: 19604124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.